Amlodipine/valsartan

Amlodipine/valsartan
Combination of
Amlodipine Calcium channel blocker
Valsartan Angiotensin II receptor antagonist
Clinical data
License data
Pregnancy
category
  • US: D (Evidence of risk)
    Routes of
    administration    		 Oral
    ATC code
    Legal status
    Legal status
    Identifiers
    CAS Number
    PubChem CID
    ChemSpider
    KEGG
      (verify)

    Amlodipine/valsartan is of an oral blood pressure lowering combination drug which combines two medications in a film-coated tablet. It contains both amlodipine, a dihydropyridine-type calcium channel blocker, and valsartan, an angiotensin II receptor antagonist (ARB or A2RA); typically formulated as the benzenesulfonate salt. Meta-analysis has shown this combination to be well tolerated and effective for the reduction of blood pressure.[1]

    The combination was originally patented by Novartis Pharmaceuticals under the brand name Exforge. The patent expired in September 2012.[2]

    Amlodipine/valsartan is available in different dose preparations: 5 mg/80 mg, 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10/320 mg of amlodipine and valsartan, respectively.

    The combination is also available with included hydrochlorothiazide, for patients who need a three drug regimen to manage their blood pressure.

    References

    1. ↑ Eckert, Siegfried; Freytag, Siegfried B.; Müller, Alfons; Klebs, Sven H. G. (2013). "Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors". Blood Pressure. 22 (sup1): 11–21. doi:10.3109/08037051.2013.793891. ISSN 0803-7051.
    2. ↑ "Generic Exforge HCT". Blood-pressure.emedtv.com. Retrieved 2012-03-05.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.